Inhibition of tumor angiogenesis by angiostatin: From recombinant protein to gene therapy

Endothelium: Journal of Endothelial Cell Research

Volumn 9, Issue 1, 2002, Pages 3-10

  Dell'Eva, Raffaella ^a   Pfeffer, Ulrich ^a   Indraccolo, S ^a   Albini, Adriana ^a   Noonan, Douglas ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Angiogenesis; Angiostatin; Gene therapy; Plasminogen; Tumor vasculature

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANGIOSTATIN K1 3; ANGIOSTATIN K1 4; B7 ANTIGEN; COLLAGEN; COLLAGEN TYPE 18; CYTOKINE; CYTOSTATIC AGENT; ENDOSTATIN; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; LENTIVIRUS VECTOR; LIPOSOME; MONOCLONAL ANTIBODY; NAKED DNA; NEUROPILIN; PEPTIDE; PLASMINOGEN; POLYPEPTIDE; PROTEIN P53; RECOMBINANT PROTEIN; RETROVIRUS VECTOR; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VIRUS VECTOR; PEPTIDE FRAGMENT;

ADJUVANT THERAPY; CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ENDOTHELIUM CELL; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEALTH CARE COST; HUMAN; LONG TERM CARE; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SOLID TUMOR; SYSTEMIC DISEASE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION; ANIMAL; GENE VECTOR; GENETICS; METHODOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ADENOVIRIDAE; ANIMALIA; LENTIVIRUS; UNIDENTIFIED RETROVIRUS;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; RECOMBINANT PROTEINS;

EID: 0042743862     PISSN: 10623329     EISSN: None     Source Type: Journal    
DOI: 10.1080/10623320210712     Document Type: Review

References (90)

1. Abdallah, B., Sachs, L., and Demeneix, B. A. 1995. Non-viral gene transfer: Applications in developmental biology and gene therapy. Biol. Cell 85(1):1-7.
2. Ali, M., Lemoine, N. R., and Ring, C. J. 1994. The use of DNA viruses as vectors for gene therapy. Gene. Ther. 1(6):367-384.
3. Andrawiss, M., Maron, A., Beltran, W., Opolon, P., Connault, E., Griscelli, F., Yeh, P., Perricaudet, M., and Devauchelle, P. 2001. Adenovirus-mediated gene transfer in canine eyes: A preclinical study for gene therapy of human uveal melanoma. J. Gene. Med. 3(3):228-239.
4. Benelli, R., Morini, M., Carrozzino, F., Ferrari, N., Minghelli, S., Santi, L., Cassatella, M., Noonan, D. M., and Albini, A. 2001. Neutrophils as a key cellular target for angiostatin: Implications for regulation of angiogenesis and inflammation. Faseb. J. 16(2):267-269.
5. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J., and Hanahan, D. 1999. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284(5415):808-812.
6. Boehm-Viswanathan, T. 2000. Is angiogenesis inhibition the Holy Grail of cancer therapy? Curr. Opin. Oncol. 12(1):89-94.
7. Browder, T., Folkman, J., and Pirie-Shepherd, S. 2000. The hemostatic system as a regulator of angiogenesis. J. Biol. Chem. 275(3):1521-1524.
8. Burns, D. P., and Temin, H. M. 1994. High rates of frameshift mutations within homo-oligomeric runs during a single cycle of retroviral replication. J. Virol. 68(7):4196-4203.
9. Cao, R., Wu, H. L., Veitonmaki, N., Linden, P., Farnebo, J., Shi, G. Y., and Cao, Y. 1999. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc. Natl. Acad. Sci. USA 96(10):5728-5733.
10. Cao, Y., Chen, A., An, S., Ji, R. W., Davidson, D., and Llinas, M. 1997. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J. Biol. Chem. 272(36):22924-22928.
11. Cao, Y., Ji, R. W., Davidson, D., Schaller, J., Marti, D., Sohndel, S., McCance, S. G., O'Reilly, M. S., Llinas, M., and Folkman, J. 1996. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J. Biol. Chem. 271(46):29461-29467.
12. Cao, Y., O'Reilly, M. S., Marshall, B., Flynn, E., Ji, R. W., and Folkman, J. 1998. Expression of angiostatin cDNA in a murine fibrosarcoma primary tumor growth and produces long-term dormancy of metastases. J. Clin. Invest. 101(5):1055-1063.
13. Chen, Z., Malhotra, P. S., Thomas, G. R., Ondrey, F. G., Duffey, D. C., Smith, C. W., Enamorado, I., Yeh, N. T., Kroog, G. S., Rudy, S., McCullagh, L., Mousa, S., Quezado, M., Herscher, L. L., and Van Waes, C. 1999. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin. Cancer Res. 5(6):1369-1379.
14. Claesson-Welsh, L., Welsh, M., Ito, N., Anand, A. B., Soker, S., Zetter, B., O'Reilly, M., and Folkman, J. 1998. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. Sci. USA 95(10):5579-5583.
15. Clapp, C., Martial, J. A., Guzman, R. C., Rentier-Delure, F., and Weiner, R. I. 1993. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133(3):1292-1299.
16. Cornelius, L. A., Nehring, L. C., Harding, E., Bolanowski, M., Welgus, H. G., Kobayashi, D. K., Pierce, R. A., and Shapiro, S. D. 1998. Matrix metalloproteinases generate angiostatin: Effects of neovascularization. J. Immunol. 161(12):6845-6852.
17. Crystal, R. G. 1995. Transfer of genes to human: Early lesson and obstacles to success. Science 270:404-410.
18. Davis, A. R., Wivel, N. A., Palladino, J. L., Tao, L., and Wilson, J. M. 2000. Construction of adenoviral vectors. Methods Mol. Biol. 135:515-523.
19. Dong, Z., Kumar, R., Yang, X., and Fidler, I. J. 1997. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88(6):801-810.
20. Felgner, J. H., Kumar, R., Sridhar, C. N., Wheeler, C., Tasi, Y. J., Border, R., Ramsey, P., Martin, M., and Felgner, P. L. 1994. Enhanced gene delivery system and mechanism studies with a novel series of cationic lipid formulation. J. Biol. Chem. 269:2550-2561.
21. Ferrara, N. 2000. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog. Horm. Res. 55:15-35.
22. Flotte, J. A., Afione, S. A., Conrad, C., McGrath, S. A., Solow, R., and Oka, H. 1993. Stable in vivo expression of the cystic fibrosis transmembrane conductane regulator with an adeno-associated virus vector. Procl. Natl. Acad. Sci. 90:1039-1044.
23. Folkman, J. 1990. What is the evidence that tumors are angiogenesis dependent? J. Natl. Canc. Inst. 82(1):4-6.
24. Folkman, J., Merler, E., Abernathy, C., and Williams, G. 1971. Isolation of a tumor factor responsible of angiogenesis. J. Exp. Med. 133:275-288.
25. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61.
26. Follenzi, A., Sabatino, G., Lombardo, A., Boccaccio, C., and Naldini, L. 2002. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene Ther. 13:243-260.
27. Gately, S., Twardowski, P., Stack, M. S., Cundiff, D. L., Grella, D., Castellino, F. J., Enghild, J., Kwaan, H. C., Lee, F., Kramer, R. A., Volpert, O., Bouck, N., and Soff, G. A. 1997. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. USA 94(20):10868-10872.
28. Gately, S., Twardowski, P., Stack, M. S., Patrick, M., Boggio, L., Cundiff, D. L., Schnaper, H. W., Madison, L., Volpert, O., Bouck, N., Enghild, J., Kwaan, H. C., and Soff, G. A. 1996. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56(21):4887-4890.
29. Griscelli, F., Li, H., Bennaceur-Griscelli, A., Soria, J., Opolon, P., Soria, C., Perricaudet, M., Yeh, P., and Lu, H. 1998. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc. Natl. Acad. Sci. USA 95(11):6367-6372.
30. Griscelli, F., Li, H., Cheong, C., Opolon, P., Bennaceur-Griscelli, A., Vassal, G., Soria, J., Soria, C., Lu, H., Perricaudet, M., and Yeh, P. 2000. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc. Natl. Acad. Sci. USA 97(12):6698-6703.
31. Gupta, S. K., Hassel, T., and Singh, J. P. 1995. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc. Natl. Acad. Sci. USA 92(17):7799-7803.
32. Gyorffy, S., Palmer, K., and Gauldie, J. 2001a. Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice. Am. J. Pathol. 159(3):1137-1147.
33. Gyorffy, S., Palmer, K., Podor, T. J., Hitt, M., and Gauldie, J. 2001b. Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: A role for combined anti-angiogenesis and immunotherapy. J. Immunol. 166(10):6212-6217.
34. Hanahan, D., and Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353-364.
35. Indraccolo, S., Minuzzo, S., Gola, E., Habeler, W., Carrozzino, F., Noonan, D., Albini, A., Santi, L., Amadori, A., and Chieco-Bianchi, L. 1999. Generation of expression plasmids for angiostatin, endostatin and TIMP-2 for cancer gene therapy. Int. J. Biol. Markers 14(4):251-256.
36. Indraccolo, S., Morini, M., Gola, E., Carrozzino, F., Habeler, W., Minghelli, S., Santi, L., Chieco-Bianchi, L., Cao, Y., Albini, A., and Noonan, D. M. 2001. Effects of angiostatin gene transfer on functional properties and in vivo growth of Kaposi's sarcoma cells. Cancer Res. 61(14):5441-5446.
37. Ji, W. R., Barrientos, L. G., Llinas, M., Gray, H., Villarreal, X., DeFord, M. E., Castellino, F. J., Kramer, R. A., and Trail, P. A. 1998a. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem. Biophys. Res. Commun. 247(2):414-419.
38. Ji, W. R., Castellino, F. J., Chang, Y., Deford, M. E., Gray, H., Villarreal, X., Kondri, M. E., Marti, D. N., Llinas, M., Schaller, J., Kramer, R. A., and Trail, P. A. 1998b. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. Faseb. J. 12(15):1731-1738.
39. Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O'Malley, K. L., and During, M. J. 1994. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8(2):148-154.
40. Kessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J., and Byrne, B. J. 1996. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. USA 93(24):14082-14087.
41. Kouraklis, G. 1999. Progress in cancer gene therapy. Acta Oncol. 38(6):675-683.
42. Kozarsky, K. F., and Wilson, J. M. 1993. Gene therapy: Adenovirus vectors. Curr. Opin. Genet. Dev. 3(3):499-503.
43. Kuo, C. J., Farnebo, F., Yu, E. Y., Christofferson, R., Swearingen, R. A., Carter, R., Von Recum, H. A., Yuan, J., Kamihara, J., Flynn, E., D'Amato, R., Folkman, J., and Mulligan, R. C. 2001. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. USA 98(8):4605-4610.
44. Lai, C. C., Wu, W. C., Chen, S. L., Xiao, X., Tsai, T. C., Huan, S. J., Chen, T. L., Tsai, R. J., and Tsao, Y. P. 2001. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest. Ophthalmol. Vis. Sci. 42(10):2401-2407.
45. Ledley, F.D. 1995. Nonviral gene therapy: The promise of genes as pharmaceutical products. Hum. Gene. Ther. 6(9):1129-1144.
46. Lesoon-Wood, L.A., Kim, W.H., Kleinman, H.K., Weintraub, B.D., and Mixson, A.J. 1995. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum. Gene. Ther. 6(4):395-405.
47. Lijnen, H.R., Ugwu, F., Bini, A., and Collen, D. 1998. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 37(14):4699-4702.
48. Liu, Y., Thor, A., Shtivelman, E., Cao, Y., Tu, G., Heath, T.D., and Debs, R.J. 1999. Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J. Biol. Chem. 274(19):13338-13344.
49. Lucas, R., Holmgren, L., Garcia, I., Jimenez, B., Mandriota, S.J., Borlat, F., Sim, B.K., Wu, Z., Grau, G.E., Shing, Y., Soff, G.A., Bouck, N., and Pepper, M.S. 1998. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92(12):4730-4741.
50. MacDonald, N.J., Murad, A.C., Fogler, W.E., Lu, Y., and Sim, B.K. 1999. The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3. Biochem. Biophys. Res. Commun. 264(2):469-477.
51. Matsuda, K.M., Madoiwa, S., Hasumi, Y., Kanazawa, T., Saga, Y., Kume, A., Mano, H., Ozawa, K., and Matsuda, M. 2000. A novel strategy for the tumor angiogenesis-targeted gene therapy: Generation of angiostatin from endogenous plasminogen by protease gene transfer. Cancer Gene. Ther. 7(4):589-596.
52. Meneses, P.I., Abrey, L.E., Hajjar, K.A., Gultekin, S.H., Duvoisin, R.M., Berns, K.I., and Rosenfeld, M.R. 1999. Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth. Clin. Cancer Res. 5(11):3689-3694.
53. Moser, T.L., Kenan, D.J., Ashley, T.A., Roy, J.A., Goodman, M.D., Misra, U.K., Cheek, D.J., and Pizzo, S.V. 2001. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc. Natl. Acad. Sci. USA 98(12):6656-6661.
54. Moser, T.L., Stack, M.S., Asplin, I., Enghild, J.J., Hojrup, P., Everitt, L., Hubchak, S., Schnaper, H.W., and Pizzo, S.V. 1999. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA 96(6):2811-2816.
55. Mulligan, R.C. 1993. The basic science of gene therapy. Science 260(5110):926-932.
56. Muzyczka, N. 1992. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158:97-129.
57. Nabel, G., Nabel, E., Yang, Z., Fox, B., Plautz, G., Gao, X., Huang, L., Shu, S., and Gordon, D. 1993. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity. Proc. Natl. Acad. Sci. 90:11307-11311.
58. Nabel, G.J., Yang, Z.Y., Nabel, E.G., Bishop, K., Marquet, M., Felgner, P.L., Gordon, D., and Chang, A.E. 1995. Direct gene transfer for treatment of human cancer. Ann. NY Acad. Sci. 772:227-231.
59. Nguyen, J.T., Wu, P., Clouse, M.E., Hlatky, L., and Terwillinger, E.F. 1998. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res. 58(24):5673-5677.
60. O'Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R., and Folkman, J. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277-285.
61. O'Reilly, M.S., Holmgren, L., Chen, C., and Folkman, J. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2(6):689-692.
62. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H., and Folkman, J. 1994. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79(2):315-328.
63. O'Reilly, M.S., Pirie-Shepherd, S., Lane, W.S., and Folkman, J. 1999. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285(5435):1926-1928.
64. Okada, H., Miyamura, K., Itoh, T., Hagiwara, M., Wakabayashi, T., Mizuno, M., Colosi, P., Kurtzman, G., and Yoshida, J. 1996. Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene. Ther. 3(11):957-964.
65. Patterson, B.C., and Sang, Q.A. 1997. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gèlatinase B/type IV collagenase (MMP-9). J. Biol. Chem. 272(46):28823-28825.
66. Pfeifer, A., Kessler, T., Silletti, S., Cheresh, D.A., and Verma, I.M. 2000. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc. Natl. Acad. Sci. USA 97(22):12227-12232.
67. Pulsinelli, G.A., and Temin, H.M. 1994. High rate of mismatch extension during reverse transcription in a single round of retrovirus replication. Proc. Natl. Acad. Sci. USA 91(20):9490-9494.
68. Redlitz, A., Daum, G., and Sage, E.H. 1999. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J. Vasc. Res. 36(1):28-34.
69. Rodolfo, M., Cato, E.M., Soldati, S., Ceruti, R., Asioli, M., Scanziani, E., Vezzoni, P., Parmiani, G., and Sacco, M.G. 2001. Growth of human melanoma xenografts is suppressed by systematic angiostatin gene therapy. Cancer Gene Ther. 8:491-496.
70. Roth, J.A., and Cristiano, R.J. 1997. Gene therapy for cancer: What have we done and where are we going? Journal of the National Cancer Institute 89(1):21-39.
71. Sacco, M.G., Caniatti, M., Cato, E.M., Frattini, A., Chiesa, G., Ceruti, R., Adorni, F., Zecca, L., Scanziani, E., and Vezzoni, P. 2000. Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer. Cancer Res 60(10):2660-2665.
72. Sacco, M.G., Cato, E.M., Ceruti, R., Soldati, S., Indraccolo, S., Caniatti, M., Scanziani, E., and Vezzoni, P. 2001. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice. Gene. Ther. 8(1):67-70.
73. Scappaticci, F.A., Smith, R., Pathak, A., Schloos, D., Lum, B., Cao, Y., Johnson, F., Engleman, E.G., and Nolan, G.P. 2001. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol. Ther. 3(2):186-196.
74. Sim, B.K., O'Reilly, M.S., Liang, H., Fortier, A.H., He, W., Madsen, J.W., Lapcevich, R., and Nacy, C.A. 1997. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 57(7):1329-1334.
75. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., and Fusenig, N.E. 1997. Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 3(11):1222-1227.
76. Smith, A.E. 1995. Viral vectors in gene therapy. Annu. Rev. Microbiol. 49:807-838.
77. Soff, G.A. 2000. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev. 19(1-2):97-107.
78. Sun, X., Kanwar, J.R., Leung, E., Lehnert, K., Wang, D., and Krissansen, G.W. 2001. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene. Ther. 8(10):719-727.
79. Suzuki, M., Singh, R.N., and Crystal, R.G. 1996. Regulatable promoters for use in gene therapy applications: Modification of the 5′-flanking region of the CFTR gene with multiple cAMP response elements to support basal, low-level gene expression that can be upregulated by exogenous agents that raise intracellular levels of cAMP. Hum. Gene. Ther. 7(15):1883-1893.
80. Tanaka, T., Cao, Y., Folkman, J., and Fine, H.A. 1998. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res. 58(15):3362-3369.
81. Tenenbaum, L., Darling, J.L., and Hooghe-Peters, E. 1994. Adeno-associated virus (AAV) as a vector for gene transfer into glial cells of the human central nervous system. Gene. Ther. 1(Suppl 1):S80.
82. Tolstoshev, P. 1993. Gene therapy, concepts, current trials and future directions. Annu. Rev. Pharmacol. Toxicol. 33:573-596.
83. Troyanovsky, B., Levchenko, T., Mansson, G., Matvijenko, O., and Holmgren, L. 2001. Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation. J. Cell Biol. 152(6):1247-1254.
84. Wang, S., and Vos, J.M. 1996. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J. Virol. 70(12):8422-8430.
85. Weidner, N., Semple, J., Welch, W., and Folkman, J. 1991. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. New Engl. J. Med. 324(1):1-8.
86. Whartenby, K.A., Abboud, C.N., Marrogi, A.J., Ramesh, R., and Freemann, S.M. 1995. Biology of disease: The biology of cancer gene therapy. Lab. Invest. 72: 131-145.
87. Wickham, T.J., Carrion, M.E., and Kovesdi, I. 1995. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene. Ther. 2(10):750-756.
88. Wilson, J.M. 1996. When bad gene transfer is good. J. Clin. Invest. 98(11):2435.
89. Wivel, N.A. 1993. Regulatory considerations for gene-therapy strategies and products. Trends Biotechnol. 11(5):189-191.
90. Wu, Z., O'Reilly, M.S., Folkman, J., and Shing, Y. 1997. Suppression of tumor growth with recombinant murine angiostatin. Biochem. Biophys. Res. Commun. 236(3):651-654.